Cyclazodone is a stimulant of the 4-oxazolidinone class, a cyclopropyl derivative of pemoline, identified by CAS number 14461-91-7 and PubChem compound ID 135438121.(1) It has never been approved for therapeutic use and no human trial of it has been published; what is known about it comes from a 1960s patent, animal tests described in that patent, and its relationship to pemoline.
The patent describes cyclazodone as a central nervous system stimulant and appetite suppressant in mice and rats. No published binding, uptake or release assay has measured which receptors or transporters it acts on, so the mechanisms quoted online (TAAR1, serotonin, norepinephrine) are untested. Pemoline, its parent compound, acts on dopamine in animals; that cyclazodone does the same is inferred, not measured.
The cognitive effects listed online (focus, wakefulness, mood, verbal fluency) come from user accounts only. The published human safety data on this family are a 2022 case report of toxicity in a man who took about 5 g of its N-methyl analogue over 5 days. Onset, duration and half-life of cyclazodone itself have not been measured, and the 4 to 6 hour half-life and 8 hour duration quoted online have no published source.
Table of Contents
Cyclazodone in Summary
Cyclazodone is a research stimulant with animal-reported stimulant and appetite-suppressing activity and no controlled human data. Its parent compound pemoline was withdrawn from the US market for safety reasons, and a 2022 case report on cyclazodone’s N-methyl analogue documented involuntary movements, a fast heart rate and heart-conduction changes.
Stimulants as a class raise heart rate and blood pressure, so heart disease and hypertension are reasons to avoid an unapproved stimulant. The caution table under the side-effects heading lists further groups.
Reported in animals (patent text)
- Rat ED50 values that the patent calls very similar to amphetamine (3.1 mg/kg for the compound against 2.6 mg/kg for d-amphetamine; animal data)
- Appetite-suppressing (anorexigenic) activity stated in the patent (animal data)
- Antagonism of reserpine-induced sedation in mice, an animal screening test
Not established or of concern
- No human efficacy or safety trial of cyclazodone
- No approved medical use, human half-life, onset time or dose
- Pemoline, the parent compound, caused liver failure and was withdrawn
- Toxicity reported in a 2022 case of its N-methyl analogue
What Is Cyclazodone?
Cyclazodone, also called cyclopropylpemoline or N-cyclopropylpemoline, is a stimulant of the 4-oxazolidinone class with the formula C12H12N2O2.
- Names: cyclazodone (international nonproprietary name), cyclopropylpemoline, ciclazodona; systematic name 2-cyclopropylimino-5-phenyl-1,3-oxazolidin-4-one
- Formula and weight: C12H12N2O2, 216.24 g/mol
- Identifiers: CAS 14461-91-7, PubChem CID 135438121
- Class: 4-oxazolidinone stimulant, a cyclopropyl derivative of pemoline
- Origin: US patent 3,609,159, assigned to Les Laboratoires Dausse of Paris, filed 1967, granted 1971
- Medicinal product: none; never approved for therapeutic use
- Human half-life, onset, duration: not established in published studies
- Human dose: none established (see the dosage section)
- Molecular targets: not measured; monoamine activity inferred from pemoline
- Legal status: see the legal section
US patent 3,609,159 names Les Laboratoires Dausse of Paris as assignee, records French priority filings from 1963, and was filed in 1967 and granted in 1971.(2) Statements that American Cyanamid created cyclazodone are not supported by that text: the American Cyanamid documents it lists are earlier US patents on related oxazolinones. A 2026 toxicokinetic paper describes cyclazodone as the closest structural analogue of pemoline, developed in the 1960s, and never approved for therapeutic use.(3)
The patent states that the cyclopropylamino compound is much more potent than the unsubstituted amino compound (the pemoline structure) and four to five times more active than the ethylamino analogue. The figure of 3 to 5 times pemoline repeated online does not appear in the patent text. The patent reports stimulant and appetite-suppressing activity in animals. It also states that the cyclopropylamino compound has a much more favorable therapeutic index and margin of safety than the other 5-phenyl-2-amino-4-oxazolinones, which includes the unsubstituted (pemoline) structure; this is the patent applicants’ animal claim; no human study compares cyclazodone with pemoline, and the patent’s animal comparison is the applicants’ own claim.(2)
Cyclazodone vs pemoline
| Attribute | Pemoline | Cyclazodone |
|---|---|---|
| Medical approval | Prescription ADHD drug in the US, later listed among drug products withdrawn or removed from the market for safety or effectiveness.(4) | Never approved |
| Human half-life | About 12 hours.(5) | Not established |
| Human trials | Controlled trials exist (described under the uses heading) | None published |
| Mechanism | Dopaminergic in animals; exact mechanism in man not known | Not measured |
| Liver failure | Boxed warning on the label; cases reported (see side effects) | Not studied; concern is inferred from the structural relationship |
| US schedule | Schedule IV stimulant.(6) | Not named in the Schedule II list (21 CFR 1308.12) or the Schedule IV list (21 CFR 1308.14) |
Cyclazodone vs Adderall
No study compares cyclazodone with Adderall (mixed amphetamine salts) in people; the patent’s only comparison is an animal test against d-amphetamine, with ED50 3.1 mg/kg against 2.6 mg/kg that the patent calls very similar (animal data). Adderall is an approved ADHD and narcolepsy medicine with human data in its label; cyclazodone is not.
| Attribute | Adderall | Cyclazodone |
|---|---|---|
| Medical approval | Label indication: ADHD and narcolepsy.(7) | Never approved |
| Human trials | Human pharmacokinetic data are in the label (single 10 or 30 mg doses in healthy volunteers). | None published |
| US schedule | Schedule II; amphetamine is listed in 21 CFR 1308.12.(8) | Not named in the Schedule II list (21 CFR 1308.12) or the Schedule IV list (21 CFR 1308.14) |
| Mechanism | Amphetamines are thought to block norepinephrine and dopamine reuptake and increase their release | Not measured |
| User comparison | One Reddit user calls cyclazodone “less euphoric than Adderall” | Anecdote, not evidence |
How Does N-Methyl-Cyclazodone Compare to Cyclazodone?
N-methyl-cyclazodone (NMC) is the N-methyl analogue of cyclazodone, 2-[cyclopropyl(methyl)amino]-5-phenyl-1,3-oxazol-4-one, and compared with cyclazodone it is a different molecule that the body converts into cyclazodone. In human liver S9 fraction (a lab preparation of liver enzymes) and in rats, NMC lost its methyl group to form cyclazodone, the only metabolite found, and the enzyme CYP2A6 did most of that work. Plasma protein binding was 36% (unbound fraction 0.64) in vitro. The authors state that clearance may differ in people with CYP2A6 genetic variants or taking strong CYP2A6 inhibitors, and that interactions with other drugs handled by the same enzymes cannot be excluded, while also stating that significant interactions via protein binding are unlikely.(3)
A 2022 clinical toxicology case confirmed cyclazodone in the urine of a man who had taken NMC, as expected from that metabolism.(9) Some or all of NMC’s effect may therefore come from cyclazodone; this is inferred, not measured.
The patent describes NMC as its example III compound. In the patent text, the sentences on cardiovascular effect in cats and dogs, lower oral toxicity than amphetamine in mice, and an appetite-suppressing effect not significantly different from amphetamine follow a reference to the example III compound, not to cyclazodone. By the order of the patent’s text, those statements appear to follow the example III compound, so they do not clearly describe cyclazodone.
Potency, onset and duration of NMC relative to cyclazodone have not been measured in a published study, and the figures quoted online for them have no published source. No human pharmacokinetic study of either compound exists, and the 2026 NMC study leaves plasma half-life and other in vivo parameters to be determined. N-methyl-cyclazodone has no approved use and no published trial for ADHD or any other condition.
How Does Cyclazodone Work In The Brain?
No published study has measured the receptors or transporters cyclazodone acts on. A 2008 pharmacology review classes cyclazodone as a stimulant with a monoamine mode of action and as a derivative of pemoline, and notes that pemoline has stimulant actions similar to dexamphetamine in a 1967 study.(10) The mode-of-action class is the reviewer’s classification, not a measurement of cyclazodone.
For pemoline, the FDA label states that studies indicate it may act in animals through dopaminergic mechanisms and that its exact mechanism and site of action in man is not known. A 2026 paper describes pemoline as a presynaptic releaser and reuptake blocker of dopamine.(3)
If cyclazodone shares pemoline’s mechanism, it would raise dopamine signalling, which would fit the wakefulness and reduced fatigue reported in animals and by users; this is inferred, not measured. Whether it acts at TAAR1 (trace amine-associated receptor 1), the serotonin transporter, the dopamine transporter or the norepinephrine transporter has not been tested, so statements that it binds TAAR1 or has high affinity for the dopamine and norepinephrine transporters have no measurement behind them.
What Is Cyclazodone Used For?
Cyclazodone has no approved use. The patent proposes it as a psychotonic drug (a stimulant of mood and energy) in depressive states, as an antifatigue agent that postpones normal sleep without inhibiting sleep at bedtime, and as an anorexigenic (appetite suppressant); the patent supports these uses with animal tests only. No cyclazodone study exists for fatigue, narcolepsy, obesity or ADHD (attention-deficit hyperactivity disorder). Narcolepsy and ADHD research belongs to pemoline, which has been investigated in clinical studies for narcolepsy and used for ADHD.
In a 10-week, double-blind crossover study of 21 adolescents (mean age 14) with ADHD, pemoline at up to 3 mg/kg/day in one to two doses produced a response in 60% of participants against 11% on placebo, an absolute difference of 49 percentage points (5.5 times the placebo response rate), with p = 0.001 on the ADHD rating scale and no adverse hepatic events.(11) This is human data for pemoline, not cyclazodone. A 10-week trial of 21 people could not detect a rare event such as liver failure, and a 2026 paper attributes pemoline’s later withdrawal to rare but idiosyncratic hepatotoxicity (liver toxicity that occurs unpredictably in a few people).
A potency advantage in animals does not establish pemoline-like effects in people. People who self-treat ADHD or fatigue with a research stimulant swap an evaluated treatment for an unmeasured product; a doctor assesses ADHD, narcolepsy and persistent fatigue.
What Are The Benefits Of Cyclazodone For Cognition?
No study has measured cyclazodone’s effect on cognition, attention or memory in people. The benefits listed online are user-reported or come from animal screening tests in the patent. The table shows what each commonly claimed benefit rests on.
| Claimed benefit | What supports it | Status |
|---|---|---|
| Focus and concentration | User reports only | Not studied in humans |
| Wakefulness, less fatigue | A rat test in the patent, endpoint not named in the patent (ED50 3.1 mg/kg for the compound against 2.6 mg/kg for d-amphetamine, which the patent calls very similar); user reports | Animal data and anecdote |
| Mood and motivation | Reserpine-antagonism screen in mice, which the patent calls an antidepressing effect at least equal to amphetamine; user reports | Animal screen and anecdote |
| Appetite suppression | Patent states anorexic activity in animals | Animal data only; no human weight data |
| Verbal fluency, sociability, empathy | User reports only | Not studied |
| Lower toxicity than amphetamine | Patent sentence concerns the N-methyl analogue (see the N-methyl section) | Not established |
Reserpine is a drug that depletes brain monoamines and sedates animals; a compound that reverses that sedation is called a stimulant or antidepressant-like in this screen, which does not predict a cognitive benefit in people. Reports from users vary and cannot be checked for compound identity, purity, dose or other drugs taken at the same time.
Where To Buy Cyclazodone Online?
Cyclazodone is sold online by research-chemical vendors as a powder, capsule and liquid, and vendor pages label it for laboratory research use only. It has no licensed medicinal product, and a research label does not change its legal position (see the legal section). The compound is also searched as cyclazadone, cycladozone, cyclazodon, cyclazadon and cyclzadone.
Purity, identity and amount per unit of research chemicals are not checked by a medicines regulator, so the label on a product is the seller’s statement and not a verified one.
What Do People Say About Cyclazodone On Reddit?
Reddit posts about cyclazodone are anecdotal: the compound, purity, amount and other drugs taken cannot be verified, and the posts are not evidence of efficacy or safety. Common themes are strong wakefulness, a long duration, a modest mood lift and, in one account, an onset of 30 to 40 minutes on an empty stomach. Two posts are quoted below.
Polaco157 wrote:
“As I figured it wud, the adrafinil significantly potentiated the effects. But the cyclazodone on its own was still very impressive. On an empty stomach, it kicks in ~30-40min. Lasts about 8hrs from the little I’ve seen. It provides strong wakefulness and stimulation.”
serduv wrote:
“It’s less euphoric than Adderall but extremely potent and functional. It absolutely does what you want it to do if you’re trying to function at a decent level and/or prolong wakefulness. Very clean. It does elevate the mood just a bit as well – just not to where it’s outside of normal…”
The first user combined cyclazodone with adrafinil, a modafinil precursor. Combining two stimulant-type drugs is expected, from their mechanisms, to add cardiovascular load; this has not been studied for the pair.
How Do You Take Cyclazodone For Cognitive Enhancement?
No published protocol defines how cyclazodone is taken. No human study sets a dose, a time of day, a food interaction, a duration of use or a cycling schedule, so advice on any of these has no published basis.
The patent tested oral, intraperitoneal (injected into the abdominal cavity) and subcutaneous routes in animals. No study has tested smoking or insufflation, and no safety data exist for them.
Pemoline’s FDA label gives a half-life of about 12 hours and lists insomnia as its most frequently reported side effect. Cyclazodone’s own half-life is unmeasured; a long-acting stimulant taken late in the day would be expected to disturb sleep (inferred from the class). The advice to cycle use every few days to prevent tolerance has no published support for cyclazodone.
What Is The Recommended Dosage For Cyclazodone?
No recommended dose of cyclazodone exists: there is no label, no human dose-finding study and no regulator-reviewed dosing text. The dose information that does exist is listed in order of strength.
- Patent-proposed unit doses (never tested in people): the patent, filed in 1967, suggests tablets of 1 to 30 mg and capsules of 1 to 60 mg (resin-bound form) for cyclazodone, and about 15 to 60 mg a day where stimulation of the central nervous system is particularly sought.(2) The patent gives no human trial behind these figures, and this range is not a dose to use. The range is wider than the estimated 57 mg animal equivalent below, and a patent statement is not evidence of safety or efficacy.
- Human study dose: none for cyclazodone. The human trial described under the uses heading gave pemoline, not cyclazodone, at up to 3 mg/kg/day in one to two doses, with a mean dose of 181.1 mg at the end of follow-up in adolescents with ADHD; that dose does not transfer to cyclazodone.
- Animal dose and estimated human equivalent: in the patent’s reserpine test, mice received cyclazodone orally at 0.010 g/kg, which is 10 mg/kg. Body-surface-area conversion uses HED (human equivalent dose, mg/kg) = animal dose x (animal Km / human Km), with Km (a body-surface-area conversion factor) of 3 for mouse and 37 for human: 10 x 3/37 = 0.811 mg/kg, and 0.811 x 70 = 56.8 mg, about 57 mg for a 70 kg adult. This is an estimated equivalent, not a tested dose, and one mouse screening test does not establish a safe or effective human dose. Neither the patent range nor this estimate is a dose to use; no safe human dose is known.
- Anecdotal community amounts: user-reported amounts differ widely, cannot be verified and are not reproduced here.
The published human exposure report is the 2022 case, in which about 5 g of NMC over 5 days (an average of about 1 g per day) was followed by hospital treatment; the side-effects section gives the findings.
What Are The Side Effects Of Cyclazodone?
No controlled study has recorded cyclazodone’s side effects in people. Documented human toxicity comes from one case report of N-methyl-cyclazodone, and the wider hazard picture comes from pemoline.
| Finding | Compound and source type | Detail |
|---|---|---|
| Toxicity after self-administration | N-methyl-cyclazodone, one human case report (2022) | A 38-year-old man who took about 5 g over 5 days arrived with uncontrollable body movements and palpitations. He had choreiform (dance-like) movements, a heart rate of 110 per minute, blood pressure of 150/90 mmHg, a QRS interval of 140 ms and a QTc of 526 ms (both ECG measures of heart-conduction timing), creatine kinase 2954 U/L (a muscle-damage marker) and ALT 104 U/L (a liver enzyme). He was treated with fluids, lorazepam, sodium bicarbonate and magnesium, and symptoms resolved by hospital day 3. He also took fluoxetine and aripiprazole, and the report is a single case, not a rate. |
| Liver failure | Pemoline, FDA label | 15 cases of acute hepatic failure were reported to the FDA after marketing began in 1975; as of December 1998, 12 of the 15 (80.0%) had ended in death or liver transplantation. These are spontaneous reports, not an incidence. The label bars use in impaired liver function. |
| Other label reactions | Pemoline, FDA label | Insomnia was the most frequently reported side effect; the label also lists anorexia and weight loss, hallucinations, dyskinetic (abnormal involuntary) movements, headache, irritability, seizures and tics. |
| Other pemoline toxicity | Pemoline, 2022 case report discussion | The report links pemoline toxicity to choreoathetosis and rhabdomyolysis (muscle breakdown). |
| Acute oral toxicity classification | Cyclazodone, one company’s hazard notification | One notification to the European Chemicals Agency classifies cyclazodone as toxic if swallowed. This is a regulatory hazard label from one company, not human data. |
Effects reported by users or expected from stimulants
Users and stimulant pharmacology point to a faster heart rate, higher blood pressure, dry mouth, headache, frequent urination, teeth grinding, muscle cramps, a higher body temperature, reduced appetite, insomnia, anxiety and irritability. After the effect fades, fatigue and low mood are commonly reported, and stimulants in general can cause paranoia and psychosis at high or repeated doses. These are commonly reported for stimulants and by cyclazodone users; none was measured in a cyclazodone study.
Abuse and dependence potential of cyclazodone have not been studied, so statements that it has low abuse potential or causes no physical dependence have no published basis.
Who should avoid cyclazodone or ask a doctor
| Group or situation | Caution | Basis |
|---|---|---|
| Liver disease | Avoid | Pemoline label bars use in impaired liver function; cyclazodone’s liver effects are unknown |
| Heart disease, high blood pressure, QT prolongation | Avoid; ask a doctor | Expected stimulant effects; heart-conduction changes in the NMC case |
| Pregnancy and breastfeeding | Avoid; no data | Pemoline label: no adequate studies in pregnant women; rats had more stillbirths and lower offspring survival at 37.5 mg/kg/day |
| Children and adolescents | Avoid; no data | A 2022 toxicology report links pemoline to liver damage in children; no cyclazodone data |
| MAO inhibitors, antidepressants and other serotonergic or stimulant drugs | Avoid; ask a pharmacist or doctor | Expected, from monoamine mechanisms; not studied for cyclazodone |
| Seizure disorders and antiepileptic drugs | Ask a doctor | Pemoline label: lowered seizure threshold reported with antiepileptic drugs |
| Bipolar disorder, psychosis, anxiety, tics | Avoid; ask a doctor | Pemoline label: clinical experience suggests exacerbation of behaviour and thought disorder in psychotic children, and tics are reported; the NMC case patient had bipolar disorder |
| Kidney disease | Ask a doctor | Pemoline label: caution in significantly impaired renal function |
| Alcohol and sedatives | Avoid combining | Alcohol and stimulants together dull the sense of intoxication, and both strain the heart (inferred) |
| Anticoagulants, surgery, thyroid disease, blood-pressure and diabetes drugs | Ask a pharmacist or doctor | Stimulant effects on heart rate, blood pressure and appetite interact with these drug classes; not studied for cyclazodone |
| Drugs cleared by CYP enzymes | Ask a pharmacist | Interactions cannot be excluded (2026 NMC study) |
| Allergy or hypersensitivity | Avoid if reactions to pemoline are known | Pemoline label bars use with known hypersensitivity |
What Nootropics Are Similar To Cyclazodone?
Pemoline is cyclazodone’s closest relative by structure. Modafinil and armodafinil are similar in intended effect, promoting wakefulness, but unrelated in structure, and they have human trial and regulatory evidence that cyclazodone lacks.
Modafinil, sold as Provigil, is a prescription medicine for sleep disorders such as narcolepsy, and 21 CFR 1308.14 lists it as a Schedule IV stimulant. Armodafinil, sold as Nuvigil, is its R-enantiomer. Both are understood to raise dopamine signalling by blocking its reuptake, and both have licensed medical uses and human trial data that cyclazodone lacks. Adrafinil, a modafinil precursor, has its own page: adrafinil, as do fladrafinil and flmodafinil.
No head-to-head study compares modafinil or armodafinil with cyclazodone, so statements that one has fewer side effects or a different mechanism than the other are untested. The types of nootropics and nootropics list pages place stimulant-type compounds beside the other classes.
What Brain Supplements Can Cyclazodone Be Stacked With?
No study has tested cyclazodone together with any supplement, so no combination is evidence-based. Pairing it with other stimulants, serotonergic drugs or MAO inhibitors is expected to add cardiovascular and nervous-system load, and interactions with drugs handled by the same liver enzymes cannot be excluded.
Online guides pair cyclazodone with Noopept, a racetam-like compound, and with branded blends. A claim that either pairing enhances the effect of cyclazodone has no study behind it.
Mind Lab Pro is a branded supplement stack that its product page describes as stimulant-free.
NooCube is a branded nootropic supplement blend.
You can get your hands on NooCube right here.
Is Cyclazodone Legal?
Cyclazodone is not named in the US Schedule IV list at 21 CFR 1308.14, which does name pemoline and modafinil, and it has no approval as a medicine; in the UK and in sport the answer depends on general rules, set out below.
The Federal Analogue Act treats a controlled substance analogue intended for human consumption as a Schedule I substance.(12) The definition of an analogue in 21 U.S.C. 802(32) is keyed throughout to substances in Schedule I or II.(13) Pemoline is Schedule IV, so resemblance to pemoline does not by itself meet that definition, and the idea that cyclazodone falls under the Act as an analogue of a Schedule IV substance misreads the statute. The effect-based parts of the definition compare a substance with Schedule I or II drugs, which include amphetamine, so the Act is not excluded on effect alone. Whether any particular substance counts as an analogue is decided case by case by the courts, and nothing here is legal advice.
In the UK, the Psychoactive Substances Act 2016 defines a psychoactive substance as any substance capable of producing a psychoactive effect that is not exempted.(14) It makes intentionally supplying such a substance an offence where it is likely to be consumed for its psychoactive effects.(15) Controlled drugs and medicinal products are among the exemptions.(16) The Act defines substances by effect, not by compound name, so no published list says whether cyclazodone or N-methyl-cyclazodone is covered, and that question is a legal one for each product.
In sport, cyclazodone is absent by name from WADA’s 2026 Prohibited List, while pemoline appears among the stimulants prohibited in competition, and the class closes with “other substances with a similar chemical structure or similar biological effect(s)”.(17) A 2008 review table of in-competition stimulants listed cyclazodone by name. A 2025 review placed both cyclazodone and N-methyl-cyclazodone among substances presumed to meet WADA criteria through pemoline; that is the review authors’ assessment, not a WADA ruling.(18) For athletes under anti-doping rules the status is unresolved, and the anti-doping organisation gives the ruling. Rules in other countries differ and change.
Frequently Asked Questions (FAQ)
Short answers on onset, feel, half-life, safety, legal status, testing, ADHD, alcohol and weight.
How Long Does It Take For Cyclazodone To Work?
Cyclazodone’s onset has not been measured in a published study. One user report quotes about 30 to 40 minutes on an empty stomach and about 8 hours of effect; this is anecdotal and unverified.
How Does Cyclazodone Make You Feel?
Cyclazodone’s subjective effects have not been recorded in a controlled study. Users describe alertness, focus, long wakefulness and a mild mood lift, and stimulant effects such as a faster heart rate, jitteriness and anxiety are expected (anecdotal and inferred). One user calls it less euphoric than Adderall; euphoria and abuse potential have not been studied (anecdotal).
What’s The Half-Life Of Cyclazodone?
Cyclazodone’s half-life has not been published, and the 4 to 6 hours quoted online has no source. Pemoline’s FDA label gives about 12 hours for pemoline, which is a different compound.
Is It Safe To Use Cyclazodone?
Cyclazodone’s safety in humans has not been studied. Documented human toxicity involves a 2022 case report of its N-methyl analogue, and its parent compound pemoline was withdrawn from the US market over rare liver toxicity. Liver injury from cyclazodone is a concern by analogy and has not been shown. Stimulant risks are a matter for a doctor.
Is Cyclazodone A Controlled Substance?
Cyclazodone is not named in the US Schedule IV stimulant list, where pemoline is listed. The Federal Analogue Act is keyed to Schedule I and II substances, not Schedule IV. UK law and sport rules work through general definitions; the legal section sets out each.
Can Cyclazodone Be Detected In A Drug Test?
In the 2022 N-methyl-cyclazodone case, a urine immunoassay was negative for amphetamines, and liquid chromatography with high-resolution mass spectrometry identified cyclazodone as the metabolite. No routine screening result for cyclazodone itself has been published.
Can Cyclazodone Be Used for ADHD?
Cyclazodone is not approved for ADHD and has not been tested for it in any published trial. Its parent compound pemoline was tested in a 21-adolescent crossover trial and later withdrawn over rare liver toxicity.
Can I Drink Alcohol While Taking Cyclazodone?
Alcohol and cyclazodone have not been studied together. Alcohol dulls the sense of intoxication and stimulants raise heart rate and blood pressure, so combining them is expected to add cardiovascular strain (inferred).
Can Cyclazodone Cause Weight Loss?
The patent states appetite-suppressing activity in animals, and pemoline’s label lists anorexia and weight loss. No human weight data exist for cyclazodone, and weight loss is not a supported use.
Conclusion
Cyclazodone is an unapproved, pemoline-derived stimulant whose published evidence is a 1960s patent with animal tests and no human trial.
What is known in people comes from one toxicity report on its N-methyl analogue and from its relative pemoline, which was withdrawn in the US over rare liver toxicity. The benefits, doses, half-life and onset quoted online are anecdotal or unmeasured, and US, UK and sport rules are set out above.
Evaluated options for ADHD, fatigue or focus are a matter for a doctor.
Cyclazodone
Do you always feel tired and unable to focus? Check out Cyclazodone, a potent derivative of the nootropic and psychostimulant compound Pemoline.
4.5
- National Center for Biotechnology Information. “Cyclazodone | C12H12N2O2 | CID 135438121.” PubChem, 27 June 2026, https://pubchem.ncbi.nlm.nih.gov/compound/Cyclazodone↩
- Guidicelli, Don Pierre, and Henry Najer. “5-Phenyl-2-Cyclopropylamino-4-Oxazolinone, and Process for Making the Same.” United States Patent 3,609,159, Les Laboratoires Dausse, 28 Sept. 1971, https://patents.google.com/patent/US3609159A/en↩↩↩
- Gampfer, Tanja M., et al. “Toxicokinetic Studies of the Two Stimulants M-ALPHA and N-Methyl-cyclazodone Using In Vitro and In Vivo Tools.” Metabolites vol. 16,5 291. 23 Apr. 2026, doi:10.3390/metabo16050291↩↩↩
- U.S. Food and Drug Administration. “21 CFR 216.24 Drug products withdrawn or removed from the market for reasons of safety or effectiveness.” eCFR, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24↩
- U.S. Food and Drug Administration. “CYLERT (pemoline) Prescribing Information.” Drugs@FDA, 2003, https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/016832s022_017703s018lbl.pdf↩
- Drug Enforcement Administration. “21 CFR 1308.14 Schedule IV.” eCFR, https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFRf62f8e189108c4d/section-1308.14↩
- Teva Pharmaceuticals USA, Inc. “Adderall (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate) Tablets: Prescribing Information.” DailyMed, National Library of Medicine, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81↩
- Drug Enforcement Administration. “21 CFR 1308.12 Schedule II.” eCFR, https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFRf62f8e189108c4d/section-1308.12↩
- Basile, J., et al. “Toxicity from the NPS N-Methyl-Cyclazodone with Laboratory Confirmation – A Dance Befitting St. Vitus.” CFSRE, American Academy of Clinical Toxicology 2022 Conference abstract, 25 Apr. 2022, https://www.cfsre.org/resources/presentations/toxicity-from-the-nps-n-methyl-cyclazodone-with-laboratory-confirmation-a-dance-befitting-st-vitus↩
- Docherty, J. R. “Pharmacology of Stimulants Prohibited by the World Anti-Doping Agency (WADA).” British Journal of Pharmacology vol. 154,3 606-22. June 2008, doi:10.1038/bjp.2008.124↩
- Bostic, Jeff Q., et al. “Pemoline Treatment of Adolescents with Attention Deficit Hyperactivity Disorder: A Short-Term Controlled Trial.” Journal of Child and Adolescent Psychopharmacology vol. 10,3 205-16. 2000, doi:10.1089/10445460050167313↩
- Office of the Law Revision Counsel. “21 U.S.C. 813 Treatment of controlled substance analogues.” United States Code, https://www.law.cornell.edu/uscode/text/21/813↩
- Office of the Law Revision Counsel. “21 U.S.C. 802 Definitions.” United States Code, https://uscode.house.gov/us/usc/119-138/t21/s802/↩
- UK Parliament. “Psychoactive Substances Act 2016, section 2.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/2↩
- UK Parliament. “Psychoactive Substances Act 2016, section 5.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/5↩
- UK Parliament. “Psychoactive Substances Act 2016, Schedule 1.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/schedule/1↩
- World Anti-Doping Agency. “World Anti-Doping Code International Standard: Prohibited List 2026.” WADA, Sept. 2025, https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf↩
- Pokrywka, Andrzej, et al. “‘Brain Doping’ Substances: Prohibited or Not in Sports?” Biology of Sport vol. 42,4 189-201. 14 May 2025, doi:10.5114/biolsport.2025.150047↩